• Je něco špatně v tomto záznamu ?

Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting With Epidermal Growth Factor (EGF) Signaling

A. Carazo, J. Dusek, O. Holas, J. Skoda, L. Hyrsova, T. Smutny, T. Soukup, M. Dosedel, P. Pávek,

. 2018 ; 9 (-) : 993. [pub] 20181011

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001607

The constitutive androstane receptor (CAR) is a nuclear receptor involved mainly in xenobiotic and endobiotic metabolism regulation. CAR is activated directly by its ligands via the ligand binding domain (LBD) or indirectly by inhibition of the epidermal growth factor (EGF) signaling. We found that leflunomide (LEF) and its main metabolite teriflunomide (TER), both used for autoimmune diseases treatment, induce the prototype CAR target gene CYP2B6 in primary human hepatocytes. As TER was discovered to be an EGF receptor antagonist, we sought to determine if TER is an indirect activator of CAR. In primary human hepatocytes and in differentiated HepaRG cells, we found that LEF and TER up-regulate CAR target genes CYP2B6 and CYP3A4 mRNAs and enzymatic activities. TER stimulated CAR+A mutant translocation into the nucleus but neither LEF nor TER activated the CAR LBD, CAR3 variant or pregnane X receptor (PXR) in gene reporter assays. Interestingly, TER significantly up-regulated CAR mRNA expression, a result which could be a consequence of both EGF receptor and ELK-1 transcription factor inhibition by TER or by TER-mediated activation of glucocorticoid receptor (GR), an upstream hormonal regulator of CAR. We can conclude that TER is a novel indirect CAR activator which through EGF inhibition and GR activation controls both detoxification and some intermediary metabolism genes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001607
003      
CZ-PrNML
005      
20190118115449.0
007      
ta
008      
190107s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2018.00993 $2 doi
035    __
$a (PubMed)30364229
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Carazo, Alejandro $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Prague, Czechia. Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czechia.
245    10
$a Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting With Epidermal Growth Factor (EGF) Signaling / $c A. Carazo, J. Dusek, O. Holas, J. Skoda, L. Hyrsova, T. Smutny, T. Soukup, M. Dosedel, P. Pávek,
520    9_
$a The constitutive androstane receptor (CAR) is a nuclear receptor involved mainly in xenobiotic and endobiotic metabolism regulation. CAR is activated directly by its ligands via the ligand binding domain (LBD) or indirectly by inhibition of the epidermal growth factor (EGF) signaling. We found that leflunomide (LEF) and its main metabolite teriflunomide (TER), both used for autoimmune diseases treatment, induce the prototype CAR target gene CYP2B6 in primary human hepatocytes. As TER was discovered to be an EGF receptor antagonist, we sought to determine if TER is an indirect activator of CAR. In primary human hepatocytes and in differentiated HepaRG cells, we found that LEF and TER up-regulate CAR target genes CYP2B6 and CYP3A4 mRNAs and enzymatic activities. TER stimulated CAR+A mutant translocation into the nucleus but neither LEF nor TER activated the CAR LBD, CAR3 variant or pregnane X receptor (PXR) in gene reporter assays. Interestingly, TER significantly up-regulated CAR mRNA expression, a result which could be a consequence of both EGF receptor and ELK-1 transcription factor inhibition by TER or by TER-mediated activation of glucocorticoid receptor (GR), an upstream hormonal regulator of CAR. We can conclude that TER is a novel indirect CAR activator which through EGF inhibition and GR activation controls both detoxification and some intermediary metabolism genes.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dusek, Jan $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Prague, Czechia.
700    1_
$a Holas, Ondrej $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Charles University, Prague, Czechia.
700    1_
$a Skoda, Josef $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Prague, Czechia.
700    1_
$a Hyrsova, Lucie $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Prague, Czechia.
700    1_
$a Smutny, Tomas $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Prague, Czechia.
700    1_
$a Soukup, Tomas $u Division of Rheumatology, 2nd Department of Internal Medicine - Gastroenterology, Faculty of Medicine, University Hospital in Hradec Kralove, Charles University, Prague, Czechia.
700    1_
$a Dosedel, Martin $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Prague, Czechia.
700    1_
$a Pávek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Prague, Czechia.
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 9, č. - (2018), s. 993
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30364229 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190118115704 $b ABA008
999    __
$a ind $b bmc $g 1365418 $s 1039730
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c - $d 993 $e 20181011 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace